Focused On-demand Library for Transcription factor SOX-5

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
P35711

UPID:
SOX5_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P35711; B7Z8V0; F5H5B0; Q86UK8; Q8J017; Q8J018; Q8J019; Q8J020; Q8N1D9; Q8N7E0; Q8TEA4

BACKGROUND:
The transcription factor SOX-5 is integral to the development of cartilage, binding to enhancers and super-enhancers of genes vital for this process. It works in tandem with SOX6 to support SOX9 in activating cartilage-specific gene expression, crucial for chondrocyte differentiation and skeletal development. SOX-5's role extends to maintaining chondroblast proliferation and influencing chondrocyte hypertrophy, highlighting its importance in cartilage formation and maintenance.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in chondrogenesis and association with Lamb-Shaffer syndrome, SOX-5 represents a promising target for therapeutic intervention. Exploring SOX-5's mechanisms could unveil new avenues for treating developmental and skeletal disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 767 of 8789